These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer. Cho BC; Chiu CH; Massarelli E; Buchschacher GL; Goto K; Overbeck TR; Loong HHF; Chee CE; Garrido P; Dong X; Fan Y; Lu S; Schwemmers S; Bordogna W; Zeuner H; Osborne S; John T Lung Cancer; 2024 Feb; 188():107442. PubMed ID: 38171156 [TBL] [Abstract][Full Text] [Related]
23. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. Drilon A; Siena S; Dziadziuszko R; Barlesi F; Krebs MG; Shaw AT; de Braud F; Rolfo C; Ahn MJ; Wolf J; Seto T; Cho BC; Patel MR; Chiu CH; John T; Goto K; Karapetis CS; Arkenau HT; Kim SW; Ohe Y; Li YC; Chae YK; Chung CH; Otterson GA; Murakami H; Lin CC; Tan DSW; Prenen H; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Doebele RC; Lancet Oncol; 2020 Feb; 21(2):261-270. PubMed ID: 31838015 [TBL] [Abstract][Full Text] [Related]
24. Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population. Westphalen CB; Krebs MG; Le Tourneau C; Sokol ES; Maund SL; Wilson TR; Jin DX; Newberg JY; Fabrizio D; Veronese L; Thomas M; de Braud F NPJ Precis Oncol; 2021 Jul; 5(1):69. PubMed ID: 34285332 [TBL] [Abstract][Full Text] [Related]
26. Activity of Entrectinib in a Patient With the First Reported Sigal D; Tartar M; Xavier M; Bao F; Foley P; Luo D; Christiansen J; Hornby Z; Maneval EC; Multani P J Natl Compr Canc Netw; 2017 Nov; 15(11):1317-1322. PubMed ID: 29118225 [TBL] [Abstract][Full Text] [Related]
27. Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours. Paz-Ares L; Barlesi F; Siena S; Ahn MJ; Drilon A; Conley A; Rolfo C; Wolf J; Seto T; Doebele R; Kapre A; Chen D; McCallum S; Osborne S; Demetri G ESMO Open; 2021 Jun; 6(3):100113. PubMed ID: 33930659 [TBL] [Abstract][Full Text] [Related]
28. Neurotrophic tyrosine receptor kinase gene fusions in adult and pediatric patients with solid tumors: a clinicogenomic biobank and record linkage study of expression frequency and patient characteristics from Finland. Zhang W; Schmitz AA; Kallionpää RE; Perälä M; Pitkänen N; Tukiainen M; Alanne E; Jöhrens K; Schulze-Rath R; Farahmand B; Zong J Acta Oncol; 2024 Jul; 63():542-551. PubMed ID: 38967220 [TBL] [Abstract][Full Text] [Related]
29. Japan society of clinical oncology/Japanese society of medical oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors, cooperated by the Japanese society of pediatric hematology/oncology. Naito Y; Mishima S; Akagi K; Igarashi A; Ikeda M; Okano S; Kato S; Takano T; Tsuchihara K; Terashima K; Nishihara H; Nishiyama H; Hiyama E; Hirasawa A; Hosoi H; Maeda O; Yatabe Y; Okamoto W; Ono S; Kajiyama H; Nagashima F; Hatanaka Y; Miyachi M; Kodera Y; Yoshino T; Taniguchi H Int J Clin Oncol; 2020 Mar; 25(3):403-417. PubMed ID: 31974683 [TBL] [Abstract][Full Text] [Related]
30. NTRK Fusions Identified in Pediatric Tumors: The Frequency, Fusion Partners, and Clinical Outcome. Zhao X; Kotch C; Fox E; Surrey LF; Wertheim GB; Baloch ZW; Lin F; Pillai V; Luo M; Kreiger PA; Pogoriler JE; Linn RL; Russo PA; Santi M; Resnick AC; Storm PB; Hunger SP; Bauer AJ; Li MM JCO Precis Oncol; 2021; 1():. PubMed ID: 34036219 [TBL] [Abstract][Full Text] [Related]
31. Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors. Naito Y; Mishima S; Akagi K; Hayashi N; Hirasawa A; Hishiki T; Igarashi A; Ikeda M; Kadowaki S; Kajiyama H; Kato M; Kenmotsu H; Kodera Y; Komine K; Koyama T; Maeda O; Miyachi M; Nishihara H; Nishiyama H; Ohga S; Okamoto W; Oki E; Ono S; Sanada M; Sekine I; Takano T; Tao K; Terashima K; Tsuchihara K; Yatabe Y; Yoshino T; Baba E Int J Clin Oncol; 2023 Jul; 28(7):827-840. PubMed ID: 37212982 [TBL] [Abstract][Full Text] [Related]
32. GISTs with Cao Z; Li J; Sun L; Xu Z; Ke Y; Shao B; Guo Y; Sun Y Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612101 [TBL] [Abstract][Full Text] [Related]
33. Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer. Farago AF; Le LP; Zheng Z; Muzikansky A; Drilon A; Patel M; Bauer TM; Liu SV; Ou SH; Jackman D; Costa DB; Multani PS; Li GG; Hornby Z; Chow-Maneval E; Luo D; Lim JE; Iafrate AJ; Shaw AT J Thorac Oncol; 2015 Dec; 10(12):1670-4. PubMed ID: 26565381 [TBL] [Abstract][Full Text] [Related]
34. Case Report: A case of complete response to entrectinib in Moriyama E; Nagasu S; Tanaka T; Shimotsuura Y; Ono T; Umeno H; Akiba J; Kawahara A; Fujita F; Kawaguchi T; Miwa K Front Oncol; 2023; 13():1247435. PubMed ID: 37601665 [TBL] [Abstract][Full Text] [Related]
35. TRK Fusion Cancer: Patient Characteristics and Survival Analysis in the Real-World Setting. Bazhenova L; Lokker A; Snider J; Castellanos E; Fisher V; Fellous M; Nanda S; Zong J; Keating K; Jiao X Target Oncol; 2021 May; 16(3):389-399. PubMed ID: 33893941 [TBL] [Abstract][Full Text] [Related]
36. NTRK Fusion in Non-Small Cell Lung Cancer: Diagnosis, Therapy, and TRK Inhibitor Resistance. Liu F; Wei Y; Zhang H; Jiang J; Zhang P; Chu Q Front Oncol; 2022; 12():864666. PubMed ID: 35372074 [TBL] [Abstract][Full Text] [Related]
37. Prevalence of NTRK Fusions in Canadian Solid Tumour Cancer Patients. Silvertown JD; Lisle C; Semenuk L; Knapp C; Jaynes J; Berg D; Kaul N; Lachapelle J; Richardson L; Speevak M; Sarras H; Berman DM; Carter R; Feilotter H; Feltis T Mol Diagn Ther; 2023 Jan; 27(1):87-103. PubMed ID: 36194351 [TBL] [Abstract][Full Text] [Related]
38. NTRK fusions in solid tumours: what every pathologist needs to know. Nguyen MA; Colebatch AJ; Van Beek D; Tierney G; Gupta R; Cooper WA Pathology; 2023 Aug; 55(5):596-609. PubMed ID: 37330338 [TBL] [Abstract][Full Text] [Related]
39. Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications. Krebs MG; Blay JY; Le Tourneau C; Hong D; Veronese L; Antoniou M; Bennett I ESMO Open; 2021 Apr; 6(2):100072. PubMed ID: 33676294 [TBL] [Abstract][Full Text] [Related]
40. Detection of Novel Tyrosine Kinase Fusion Genes as Potential Therapeutic Targets in Bone and Soft Tissue Sarcomas Using DNA/RNA-based Clinical Sequencing. Hasegawa N; Hayashi T; Niizuma H; Kikuta K; Imanishi J; Endo M; Ikeuchi H; Sasa K; Sano K; Hirabayashi K; Takagi T; Ishijima M; Kato S; Kohsaka S; Saito T; Suehara Y Clin Orthop Relat Res; 2024 Mar; 482(3):549-563. PubMed ID: 38014853 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]